Emerging Strategies in Lung Cancer Screening: Blood and Beyond.
Clin Chem
; 70(1): 60-67, 2024 01 04.
Article
em En
| MEDLINE
| ID: mdl-38175587
ABSTRACT
BACKGROUND:
Although low dose computed tomography (LDCT)-based lung cancer screening (LCS) can decrease lung cancer-related mortality among high-risk individuals, it remains an imperfect and substantially underutilized process. LDCT-based LCS may result in false-positive findings, which can lead to invasive procedures and potential morbidity. Conversely, current guidelines may fail to capture at-risk individuals, particularly those from under-represented minority populations. To address these limitations, numerous biomarkers have emerged to complement LDCT and improve early lung cancer detection. CONTENT This review focuses primarily on blood-based biomarkers, including protein, microRNAs, circulating DNA, and methylated DNA panels, in current clinical development for LCS. We also examine other emerging biomarkers-utilizing airway epithelia, exhaled breath, sputum, and urine-under investigation. We highlight challenges and limitations of biomarker testing, as well as recent strategies to integrate molecular strategies with imaging technologies.SUMMARY:
Multiple biomarkers are under active investigation for LCS, either to improve risk-stratification after nodule detection or to optimize risk-based patient selection for LDCT-based screening. Results from ongoing and future clinical trials will elucidate the clinical utility of biomarkers in the LCS paradigm.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Líquidos Corporais
/
MicroRNAs
/
Neoplasias Pulmonares
Tipo de estudo:
Diagnostic_studies
/
Guideline
/
Screening_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article